Bellicum Pharmaceuticals, located near the Houston Medical Center, is engineering high-performance cellular immunotherapies and unleashing their power against a wide range of cancers, impacting more patients than ever.
Our cellular platform technology is designed to break through significant clinical barriers and activate the full power of cellular immunotherapies, with a focus on chimeric antigen receptor T-cell therapy (CAR-T).
Our cellular platform technology is designed to break through significant clinical barriers and activate the full power of cellular immunotherapies, with a focus on chimeric antigen receptor T-cell therapy (CAR-T).
Location: United States, Texas, Houston
Employees: 1-10
Total raised: $144.4M
Founded date: 2003
Investors 7
Funding Rounds 4
| Date | Series | Amount | Investors |
| 07.12.2021 | - | $35M | - |
| 27.08.2014 | Series C | $55M | - |
| 07.01.2014 | Series B | $34.4M | - |
| 08.03.2012 | Series B | $20M | - |
Mentions in press and media 15
| Date | Title | Description |
| 07.12.2021 | Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T Studies, Secures $35 Million Private Placement Equity Financing Priced at Market | HOUSTON - Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced positive interim data from its ongoing Phase 1/2 GoCAR-T clinical trials, including a ... |
| 06.12.2021 | Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market | - Confirmed partial response observed in one patient in first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 - - Favorable safety profile observed in initial dose cohort of BPX-603 in HER2+ s... |
| 06.12.2021 | Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market | - Confirmed partial response observed in one patient in first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 - - Favorable safety profile observed in initial dose cohort of BPX-603 in HER2+ s... |
| 07.12.2020 | Amid a record bad year, Bellicum keeps taking its lumps as FDA slams trial hold on CAR-T hopeful | It’s been no less than a disastrous year for Houston biotech Bellicum Pharmaceuticals after taking a scalpel to its pipeline and dumping a vast majority of its staff. Now, in an already-doomed trial of one of Bellicum’s nex... |
| 23.02.2018 | Bellicum outlines a few quick steps the FDA wants before lifting its hold on lead cell therapy, shares rise | Bellicum rocked investors at the end of last month with news that its “safer” lead cell therapy had been put on hold by the FDA. And this morning the biotech is following up with an explanation of what it needs to do to get that h... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 27.08.2014 | Bellicum Pharmaceuticals Completes $55M Series C Financing | Bellicum Pharmaceuticals, Inc., a Houston, Texas-based biotechnology company focused on developing effective cellular immunotherapies, completed a $55M Series C financing. The round brought the total capital raised since inception to $107m.... |
| 07.01.2014 | Texas' Bellicum gets $15M to expand work on gene 'switch' tech | Close to a decade after a pair of investigators from Baylor College of Medicine launched Bellicum Pharmaceuticals in Houston, the biotech has added $14.7 million to its Series B round, which will help expand an ongoing Phase I/II study of i... |
| 07.01.2014 | Bellicum Pharmaceuticals Inks $34.4M in Series B | HOUSTON, TX, Bellicum Pharmaceuticals announced today that it has completed a second and final closing of its Series B financing, securing an additional $14.7 million and bringing the total raised in the round to $34.4 million. >> ... |
| 07.01.2014 | Bellicum Pharmaceuticals Secured Additional $14.7M in Series B Financing | Bellicum Pharmaceuticals, a Houston, Texas-based developer of cell therapies to treat cancers and other serious, life-threatening diseases, secured an additional $14.7m in Series B financing. Investors in the round, which now amounts to $34... |
Show more